Bosentan for Mild Pulmonary Vascular Disease in Asd Patients.
Bosentan for Mild Pulmonary Vascular Disease in Asd Patients.
Volume overload due to left-to-right shunting in patients with atrial septal defect type
 secundum causes pulmonary vascular disease over a long period of time. Pulmonary vascular
 resistance can be assessed non-invasively using bicycle stress echocardiography. By measuring
 cardiac output and pulmonary artery pressures at different stages of exercise, a
 pressure-output plot can be obtained. The slope of the pressure-output plot reflects
 pulmonary vascular resistance. In patients undergoing ASD repair after the age of 40 years,
 pulmonary vascular resistance was higher when compared to age-matched controls, indicating
 the presence of mild pulmonary vascular disease. Bosentan has been shown to decrease
 pulmonary vascular resistance.

 The investigators hypothesize that in patients with an ASD type secundum, who underwent ASD
 repair after the age of 40 years, administration of bosentan decreases pulmonary vascular
 resistance as assessed by bicycle stress echocardiography.
1. INTRODUCTION AND RATIONALE

 1.1 MEDICAL BACKGROUND

 Atrial septal defect (ASD) represents approximately 10% of all congenital heart diseases
 and is the third most common form of congenital heart defect. The incidence of
 congenital heart disease in Belgium is 1%, with ASD accounting for 25% of the cases
 (Data from the database of congenital heart diseases UZ Leuven.) Characterized by a free
 communication between the left and the right atrium, it may take the form of an ostium
 secundum defect (in the region of the fossa ovalis); an ostium primum defect (in the
 lower part of the atrial septum and associated with mitral regurgitation) or a sinus
 venosus defect (in the upper atrial septum and associated with anomalous drainage of one
 or more pulmonary veins)

 Patients with atrial septal defect (ASD) initially present with a left-to-right shunt,
 which may cause elevated pulmonary artery pressures at rest and/or during exercise.
 However, this persistently elevated pulmonary blood-flow also causes progressive lesions
 of the pulmonary vasculature, as first described by Heath and Edwards. The earlier
 stages present with medial hypertrophy and/or intimal proliferation and are largely
 reversible after closure of the defect. Later stages, however, are irriversible: the
 origin of pulmonary arterial hypertension (PAH). Eventually, this volume and pressure
 overload of the right heart may lead to heart failure and/or arrhythmias. As PVR exceeds
 systemic resistance, the shunt is reversed (right-to-left shunt) leading to systemic
 arterial desaturation (and the related consequences: polyglobulia, hyperuricemia,
 decreased renal function and abnormal coagulation): the Eisenmenger syndrome (ES). When
 occlusive fibrotic lesions have developed later in life, closure of the ASD, although
 still feasible, may not result in complete normalization of pulmonary artery pressures.
 Moreover, it has been shown that closure after the age of 40 years is associated with
 worse outcome. It has been suggested that an abnormal increase in pulmonary artery
 pressures during exercise reflects mild pulmonary vascular disease. However, pulmonary
 artery pressures are defined by both cardiac output and pulmonary vascular resistance.
 During exercise, the relationship between pulmonary artery pressures and cardiac output
 is slightly curvilinear because of a natural distensibility of the pulmonary arterioles.
 Using bicycle stress echocardiography, pulmonary vascular resistance can be estimated
 either as a ratio of pulmonary artery pressure and cardiac output at each stage (total
 PVR) or by using linear regression analysis of the pressure-flow plots (dynamic PVR).

 Prognosis of patients with unrepaired ASDs is thought to be shortened and repair can
 avoid right ventricular (RV) failure, pulmonary hypertension, thrombo-embolic events and
 atrial dysrrhythmias. So, when the defect is discovered early, an ASD is usually closed
 in childhood, unless the defect is considered not to be clinical significant. Sometimes,
 as most patients with an isolated ASD are asymptomatic during childhood, an ASD comes to
 medical attention at an older age.

 Patients with a corrected ASD have a poorer prognosis than patients in a control group,
 especially in the presence of PAH, which confers an eightfold increased probability of
 functional limitations. In the Euroheart survey PAH was present in 12% of patients with
 a closed ASD. As PAH is a progressive disease, early diagnosis and treatment may improve
 outcome in these patients.

 A first analysis of data obtained from the registry of ASD showed that in the
 transcatheter closed ASD patients, mPAP was the only independent predictor of atrial
 arrhythmia after ASD repair. Moreover, our first prospective study showed that it is
 possible to identify patients with mild pulmonary vascular disease using stress
 echocardiography and that patients with an ASD closed at later age were unable to
 decrease pulmonary vascular resistance during exercise, resulting in a higher pulmonary
 vascular resistance at peak exercise when compared to a control group. This was
 reflected in a steeper pressure-flow plot when compared to healthy controls. Endothelin
 has shown to influence vasomotor tone, especially during exercise. Moreover, Faoro et al
 showed that bosentan decreased pulmonary vascular resistance as assessed with
 pressure-flow plots during hypoxia. Therefore, this study was designed to evaluate the
 effect of an dual endothelin receptor antagonist on total pulmonary vascular resistance
 during exercise in an older ASD patient population.

 1.2 DRUG PROFILE

 Mechanism of action

 Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both
 endothelin A and B (ET-A and ET-B) receptors. Bosentan decreases both pulmonary and
 systemic vascular resistance resulting in increased cardiac output without increasing
 heart rate.

 The neurohormone endothelin-1 (ET-1) is one of the most potent vasoconstrictors known
 and can also promote fibrosis, cell proliferation, cardiac hypertrophy, and remodeling
 and is pro-inflammatory. These effects are mediated by endothelin binding to ET-A and
 ET-B receptors located in the endothelium and vascular smooth muscle cells. ET-1
 concentrations in tissues and plasma are increased in several cardiovascular disorders
 and connective tissue diseases, including pulmonary arterial hypertension, scleroderma,
 acute and chronic heart failure, myocardial ischaemia, systemic hypertension and
 atherosclerosis, suggesting a pathogenic role of ET-1 in these diseases. In pulmonary
 arterial hypertension and heart failure, in the absence of endothelin receptor
 antagonism, elevated ET-1 concentrations are strongly correlated with the severity and
 prognosis of these diseases.

 Bosentan competes with the binding of ET-1 and other ET peptides to both ET-A and ET-B
 receptors, with a slightly higher affinity for ET-A receptors (Ki = 4.1-43 nM) than for
 ET-B receptors (Ki = 38-730 nM). Bosentan specifically antagonises ET receptors and does
 not bind to other receptors.

 1.3 RATIONALE FOR PERFORMING THE STUDY

 Although an ASD seems an easily correctable defect, patients with a repaired ASD have a
 poorer prognosis than patients in a control group, especially in the presence of PAH,
 which confers an eightfold increased probability of functional limitations. In the
 Euroheart survey PAH was present in 12% of patients with a closed ASD. Whether it is
 useful to treat mild to moderate pulmonary vascular disease after repair of an ASD with
 specific PAH treatment in order to have a positive effect on exercise capacity and even
 outcome outcome still needs to be evaluated.

 As outlined in section 1.1, the investigators were able to identify patients with mild
 pulmonary vascular disease using bicycle exercise echocardiography. Patients with an ASD
 repaired after the age of 40 years appeared to have higher PVR when compared to healthy
 controls. Moreover, in older patients a higher mPAP at diagnosis was an independent
 predictor for the occurrence of late atrial arrhythmias.

 Therefore, the present study will investigate whether bosentan has a beneficial effect
 on PVR as measured with bicycle stress echocardiography in patients with repaired ASD
 and WHO FC II mild pulmonary vascular disease using dynamic PVR as a surrogate endpoint.

 1.3.1 DOSE AND POSOLOGY

 Treatment will be initiated at a dose of 62.5 mg twice daily for 4 weeks and then
 increased to the maintenance dose of 125 mg twice daily for 12 weeks.

 Dosage in elderly patients: No dosage adjustment in required in patients over the age of
 65 years.

 2. STUDY OBJECTIVES

 The primary efficacy objective is to assess the efficacy of the dual active endothelin
 receptor antagonist bosentan in patients with WHO functional class II mild to moderate
 PAH after surgical or interventional closure of an ASD .

 3. STUDY DESIGN

 This is a prospective, monocentric, randomised, double-blind, placebo-controlled, pilot study
 to evaluate the efficacy of dual active endothelin receptor antagonist bosentan in patients
 with WHO FC II, mild pulmonary vascular disease after ASD repair.

 4 STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE

 The null hypothesis of the study is that in patients receiving specific PAH treatment no
 change in PVR is observed. This trial aims to demonstrate to efficacy of bosentan to lower
 PVR as assessed by bicycle exercise echocardiography in patients with surgically or
 transcatheter closed ASD.

 5 RANDOMISATION

 Patients will be randomly assigned to treatment groups with equal probability of assignment
 to each treatment arm (allocation ratio 1:1). The randomisation schedule will be generated
 using validated software. The investigators will remain blinded to the randomisation schedule
 until after the final database is locked. The randomisation schedule will be examined only if
 required by an emergency. Any such break should be documented clearly.

 6 SAMPLE SIZE CALCULATION

 As the study design is considered as a pilot trial, it primarily aims at defining means and
 standard deviations in both treatment arms in order to allow for future sample size
 calculations.
Inclusion Criteria:

 -  Signed informed consent by patient prior to initiation of any study-mandated
 procedure.

 -  Male or female patients > 40 years with atrial septal defect type secundum and > 40
 years of age at the time of repair

 -  Women of childbearing potential must have a negative pre-treatment pregnancy test and
 must use a reliable method of contraception during study treatment and for at least 3
 months after study treatment termination.

 -  Women not of childbearing potential are defined as postmenopausal (amenorrhea for at
 least 1 year), or documented surgically or naturally sterile.

 Exclusion Criteria:

 -  Pregnancy or lactation

 -  Women of child-bearing age who are sexually active without practising reliable methods
 of contraception

 -  Any disease or impairment that, in the opinion of the investigator, excludes a subject
 from participation

 -  Substance abuse (alcohol, medicines, drugs)

 -  Other medical, psychological or social circumstances that would adversely affect a
 patient's ability to participate adequately in the study or increase the risk to the
 patient or others in the case of participation

 -  Insufficient compliance

 -  Subjects who are not able to perform cardiopulmonary exercise testing

 -  ASD repair < 6 months before inclusion

 -  PAH of any aetiology other than the one specified in the inclusion criteria

 -  Impairment of organic function (renal, hepatic)

 -  Arterial hypotension (systolic blood pressure < 85 mmHg)

 -  Anaemia (Hb< 10 g/dl)

 -  Decompensated symptomatic polycythemia

 -  Thrombocytopenia (< 50000/µl)

 -  Significant valvular diseases, other than tricuspid or pulmonary regurgitation

 -  Chronic lung disease or total lung capacity < 80% of predicted value

 -  History of significant pulmonary embolism

 -  Other relevant diseases (HIV infection, Hep B/C infection)

 -  Subjects with known intolerance to bosentan or their constituents

 -  Prohibited medication: any medication listed below which has not been discontinued at
 least 30 days prior to screening

 -  Unspecified or other significant medication (glyburide or immunosuppression)

 -  Drugs to treat PAH (endothelin receptor antagonists, PDE-5 antagonists,
 prostanoids)

 -  Medication that is not compatible with bosentan or that interferes with its
 metabolism (inhibitors of CYP2C9 or CYP3A4) or that, in the investigator's
 opinion, may interfere with bosentan treatment.